PRQR is tracked by BiotechSign with a current catalyst score of 44/100 and grade D. The page summarizes 0 active signals, including 0 PDUFA, 0 insider buying, and 0 clinical trial signals, with data refreshed on 2026-07-19.
As of 2026-07-19, ProQR Therapeutics (PRQR) has a BiotechSign Catalyst Score of 44/100, rated D. The company has 0 active signals tracked by BiotechSign. BiotechSign scores combine FDA pipeline data, clinical trial activity, SEC insider filings, dilution risk, and sentiment analysis into a single catalyst grade.
This data is for informational purposes only and does not constitute financial or medical advice. Biotech and pharmaceutical stocks carry extreme risk, including binary FDA outcomes that can result in total loss. Always conduct your own due diligence. Source: BiotechSigns (biotechsign.com).
ProQR Therapeutics (PRQR) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[4], including 1 Phase 3[1], 2 Phase 2[2], 1 Phase 1[3].
Trial NCT03913143[5] evaluates sepofarsen in Leber Congenital Amaurosis 10 with a target enrollment of 36 participants.
No Form 4 insider filings for PRQR were recorded at the SEC in the past 30 days[6].